Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice

Figures & data

Figure 1. (a) Case 2 after 6 months of treatment with tralokinumab with no response, prior to reintroduction of upadacitinib. (b) Case 2 after 5 months of retreatment with upadacitinib. (c) Case 3 after 6 months of treatment with dupilumab, prior to reintroduction of upadacitinib. (d) Case 3 after 5 months of retreatment with upadacitinib.

Data availability statement

The data that support the findings of this study are openly available in Pubmed at:

1. http://doi.org/10.1038/s41572-018-0001-z, reference number 1.

2. http://doi.org/10.1038/s41573-021-00266-6, reference number 2.

3. http://doi.org/10.1016/S0140-6736(21)00588-2, reference number 3.

4. http://doi.org/10.1001/jamadermatol.2022.0029, reference number 4.

5. http://doi.org/10.1016/j.jaci.2019.11.025, reference number 6.

6. http://doi.org/10.1007/s40268-022-00396-1, reference number 7.

7. http://doi.org/10.2340/actadv.v103.5243, reference number 8.